GlassScriptPhysician profile
Devin W Kehl
NPI 1316253024
$6,944.58
in general payments reported to CMS, 2019-2025
26 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,089 · 2020: $1,196 · 2022: $164 · 2023: $535 · 2024: $991 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,088.55 | 2019 | |
| Abbott Laboratories | $1,196.10 | 2020 | |
| Novartis Pharmaceuticals Corporation | $710.67 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $366.21 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $338.40 | 2024-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.01 | 2023-2025 | Jardiance |
| Octapharma USA, INC. | $120.55 | 2023 | Panzyga |
| Janssen Pharmaceuticals, INC | $112.97 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $96.06 | 2025 | Amvuttra |
| Pfizer INC. | $76.07 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $75.89 | 2023-2025 | Evkeeza, Praluent |
| Boston Scientific Corporation | $71.69 | 2022-2024 | Bodyguardian |
| Lexicon Pharmaceuticals, INC. | $68.70 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $65.19 | 2024 | Wainua |
| Merck Sharp & Dohme LLC | $51.66 | 2022-2024 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $44.78 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $33.33 | 2023 | |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $27.39 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $24.97 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.54 | 2023 | Lifevest |
| Kestra Medical Technology Services, INC. | $21.47 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $21.07 | 2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $20.34 | 2024 | Uptravi, Opsumit |
| Heartflow, INC. | $20.17 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Kehl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.